Search filters

List of works by Elizabeth R. Gerstner

ACTR-76. FINAL RESULTS FROM A PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

scientific article published on 6 November 2017

AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

scientific article published in November 2014

ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA.

scientific article

ATNT-14PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

scientific article

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma

scientific article published on 08 June 2020

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

scientific article published on 14 January 2020

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma

scientific article published on 23 March 2020

NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

scientific article published on 10 March 2020

Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.

scientific article

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

scientific article published on 18 June 2020

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

scientific article published on 01 June 2020

Paulina is supported by:

About Paulina

Help